Last reviewed · How we verify
Antisedan (ATIPAMEZOLE)
Antisedan (generic name: ATIPAMEZOLE) is a drug. It is currently FDA-approved.
Atipamezole is a small molecule with the chemical name 4-(2-ETHYL-2-INDANYL)IMIDAZOLE. It has been studied in clinical trials for conditions such as emergence from anesthesia and has been used in a PET study to investigate its competition with striatal [11C]ORM-13070 binding by endogenous noradrenaline.
At a glance
| Generic name | ATIPAMEZOLE |
|---|---|
| Target | Alpha-1B adrenergic receptor, Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
Common side effects
- Vomiting
- Excitement
- Apprehensiveness
- Hypersalivation
- Diarrhea
- Tremors
Key clinical trials
- Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed (PHASE1)
- Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antisedan CI brief — competitive landscape report
- Antisedan updates RSS · CI watch RSS
Frequently asked questions about Antisedan
What is Antisedan?
What is the generic name of Antisedan?
What development phase is Antisedan in?
What are the side effects of Antisedan?
What does Antisedan target?
Related
- Target: All drugs targeting Alpha-1B adrenergic receptor, Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing